MedPath

Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation

Recruiting
Conditions
Persistent Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Interventions
Device: Catheter ablation
Registration Number
NCT04088071
Lead Sponsor
Heart Rhythm Clinical and Research Solutions, LLC
Brief Summary

The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.

Detailed Description

The REAL AF Registry is an observational, prospective, multi-center, non-randomized registry designed to obtain real-world clinical experience of Paroxysmal and Persistent ablation RF technologies (e.g., THERMOCOOL SMARTTOUCH®, THERMOCOOL SMARTTOUCH® SF). Future new contact force technologies may be included as they become available in the market. Patient assessments will occur at the following time points: 1) pre-ablation, 2) procedure, 3) 10-12 weeks, 4) 6 months (monitor only) and 5) 1 year post ablation.

The objective of this registry is to assess clinical outcomes, including procedural efficiency, safety, long-term, effectiveness of RF ablations in the treatment of patients with Paroxysmal or Persistent atrial fibrillation. The outcomes of the registry are: 1) long term effectiveness defined as freedom from atrial arrhythmia recurrence post 90 day blanking period, and 2) acute and late onset complications.

Sites selected for this registry will already have the following pre and post procedure assessments as part of their standard of care:

Patient assessments at the following time points: (1) pre-ablation or baseline, (2) procedure, (3) 10-12 weeks, (4) 6 months (monitor only) and (5) 1 year post ablation.

Pre ablation/baseline assessment should include: TTE (within 6 months of procedure), CHADS2Vasc, sleep apnea, AAD status, OAC, Medical and Arrhythmia History 10-12 Week Follow-Up Office Visit: Physician evaluation, AAD status, OAC usage, repeat TTE, and Arrhythmia Reoccurrence and Treatment Assessment Monitoring: 96-hour continuous heart rhythm monitor scheduled at 6 months and 12 months post ablation, with an event monitor ordered as needed for symptomatic arrhythmias.

12 Month Follow up Office Visit: Physician evaluation, AF Type, AF Monitoring method, Sleep apnea, Post-procedure arrhythmia treatments, AF related symptoms and QOL improvement, AAD and OAC usage, CHA2DS2VASC and Arrhythmia Reoccurrence and Treatment Assessment

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
15000
Inclusion Criteria
  • Symptomatic Paroxysmal (AF episode terminate spontaneously within 7 days) or Persistent (AF sustained beyond 7 days) who, in the opinion of the investigator, are candidates for ablation for AF
  • 18 years of age or older
  • De Novo ablation procedure unless it is a repeat for a patient whose index procedure is also in the registry
  • Able and willing to participate in baseline and follow up evaluations for the full length of the registry
  • Willing and able to provide informed consent, if applicable
Exclusion Criteria
  • Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan
  • Long-standing persistent AF (AF greater than one year's duration)
  • Having a repeat ablation, unless the subject's index ablation procedure is also included in the registry
  • In the opinion of the investigator, any known contraindication to an ablation procedure

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with atrial fibrillationCatheter ablationSubjects with symptomatic PAF or PsAF who, in the opinion of the investigator, are candidates for ablation for AF, age 18 years or older, and are able and willing to comply with all pre-, post-, and follow-up testing and requirements.
Primary Outcome Measures
NameTimeMethod
Effectiveness at 12 months12 months

Freedom from atrial arrhythmia recurrence at 12 months post procedure.

Long-term SafetyPost-procedure, 3 months, and 12 months

Adverse events from post-procedure through the 12-month office visit date

Effectiveness at 90 days90 days

Freedom from atrial arrhythmia recurrence at 90 days post procedure.

Secondary Outcome Measures
NameTimeMethod
AF recurrence12 months

Recurrence seen during monitoring with Dual/ CRT Pacer or ICD; Event Monitor; LinQ; Holter; EKG; TTE

Post-procedure arrhythmia treatments12 months

Treatments for AF post-procedure

AAD Usage12 months

Antiarrhythmic drug use (and type) post procedure and 12 months

OAC usage12 months

Oral anticoagulant use at 12 months and drug type

Patient reported outcome12 months

How do you feel now compared to pre-ablation?

AF related symptoms12 months

Presence of: weakness, fluttering, SOB, fatigue, dizziness, decrease in exercise tolerance, chest pain/pressure, heart racing/palpitations, and other (yes/no)

CHA2DS2VASC12 months

An estimation of stroke risk for patients with Atrial Fibrillation. Composite score of: Age (\<65= 0; 65-74=1; \>75=2) + Sex (Female=1; Male=0) + Congestive Heart Failure (Yes =1; No=0) + Hypertension (Yes= 1; No= 0) + Stroke, Transient Ischemic Attack (TIA) or thromboembolism (Yes=2; No=0) + Vascular Disease (Yes=1; No=0) + Diabetes (Yes=1; No=0). Scores range from 0 to 9, with higher scores indicating greater risk for stroke.

Trial Locations

Locations (65)

MercyHealth

🇺🇸

Janesville, Wisconsin, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Grandview Medical Center

🇺🇸

Birmingham, Alabama, United States

Cardiology Associates of Mobile

🇺🇸

Mobile, Alabama, United States

Valley Heart Rhythm Specialists

🇺🇸

Chandler, Arizona, United States

Arrhythmia Research Group

🇺🇸

Jonesboro, Arkansas, United States

Keck School of Medicine

🇺🇸

Los Angeles, California, United States

Santa Barbara Cottage Hospital

🇺🇸

Santa Barbara, California, United States

Community Memorial Hospital

🇺🇸

Ventura, California, United States

University HealthCare Alliance

🇺🇸

Walnut Creek, California, United States

The Medical Center of Aurora

🇺🇸

Aurora, Colorado, United States

Colorado Heart and Vascular

🇺🇸

Golden, Colorado, United States

South Denver Cardiology

🇺🇸

Littleton, Colorado, United States

Ascension St. Vincent's

🇺🇸

Jacksonville, Florida, United States

HCA Florida Mercy Hospital

🇺🇸

Miami, Florida, United States

Naples Community Hospital

🇺🇸

Naples, Florida, United States

Ascension Sacred Heart

🇺🇸

Pensacola, Florida, United States

Sarasota Memorial Hospital

🇺🇸

Sarasota, Florida, United States

Baycare Health System

🇺🇸

Winter Haven, Florida, United States

Piedmont Healthcare

🇺🇸

Atlanta, Georgia, United States

Memorial Health University Medical Center

🇺🇸

Savannah, Georgia, United States

The Queen's Medical Center

🇺🇸

Honolulu, Hawaii, United States

Northshore University Health System

🇺🇸

Evanston, Illinois, United States

Prairie Education and Research

🇺🇸

Springfield, Illinois, United States

Ascension St. Vincent's Hospital

🇺🇸

Indianapolis, Indiana, United States

University of Iowa

🇺🇸

Iowa City, Iowa, United States

Norton Heart Specialists

🇺🇸

Louisville, Kentucky, United States

Baptist Health Louisville

🇺🇸

Saint Matthews, Kentucky, United States

Maine Medical Center

🇺🇸

Portland, Maine, United States

Capitol CArdiology

🇺🇸

Lanham, Maryland, United States

Brigham and Women's Hospital

🇺🇸

Boston, Massachusetts, United States

Henry Ford Health

🇺🇸

Detroit, Michigan, United States

McLaren Greater Lansing

🇺🇸

Lansing, Michigan, United States

Sparrow Clinical Research

🇺🇸

Lansing, Michigan, United States

William Beaumont Hospital

🇺🇸

Royal Oak, Michigan, United States

Michigan Heart

🇺🇸

Ypsilanti, Michigan, United States

Mississippi Baptist Medical Center

🇺🇸

Jackson, Mississippi, United States

University of Missouri

🇺🇸

Columbia, Missouri, United States

CoxHealth

🇺🇸

Springfield, Missouri, United States

Cardiovascular Associates of the Delaware Valley

🇺🇸

Haddon Heights, New Jersey, United States

Lovelace Health System

🇺🇸

Albuquerque, New Mexico, United States

Nuvance Health

🇺🇸

Poughkeepsie, New York, United States

Mission Hospital

🇺🇸

Asheville, North Carolina, United States

Novant Health Forsyth Medical Center

🇺🇸

Winston-Salem, North Carolina, United States

University of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

The Christ Hospital

🇺🇸

Cincinnati, Ohio, United States

Mount Carmel Columbus Cardiology Consultants

🇺🇸

Columbus, Ohio, United States

Oklahoma Heart Hospital

🇺🇸

Oklahoma City, Oklahoma, United States

Lancaster General Hospital

🇺🇸

Lancaster, Pennsylvania, United States

University of Pennsylvania, Penn Presbyterian Medical Center

🇺🇸

Philadelphia, Pennsylvania, United States

Allegheny Health Network

🇺🇸

Pittsburgh, Pennsylvania, United States

WellSpan Health

🇺🇸

York, Pennsylvania, United States

Upstate Cardiology

🇺🇸

Greenville, South Carolina, United States

Carolina Cardiology Associates and OnSite Clinical Solutions

🇺🇸

Rock Hill, South Carolina, United States

Baylor Scott & White Research Institute

🇺🇸

Dallas, Texas, United States

Medical City Dallas Hospital

🇺🇸

Dallas, Texas, United States

St. Mark's Hospital

🇺🇸

Salt Lake City, Utah, United States

Centra Health, Inc. dba Stroobants Cardiovascular Center

🇺🇸

Lynchburg, Virginia, United States

Bon Secours St. Marys

🇺🇸

Midlothian, Virginia, United States

CJW Medical Center

🇺🇸

Richmond, Virginia, United States

Valley Health

🇺🇸

Winchester, Virginia, United States

MultiCare Institute for Research & Innovation

🇺🇸

Tacoma, Washington, United States

University of Wisconsin

🇺🇸

Madison, Wisconsin, United States

Alberta Health

🇨🇦

Edmonton, Alberta, Canada

Southlake Regional Health Centre

🇨🇦

Newmarket, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath